Bleeding Disorders

Children with sickle cell anemia (SCA) are at risk of developing cerebral ischemia, including a high prevalence of silent cerebral infarcts (SCI), which can...

The U.S. Food and Drug Administration (FDA) has approved BAY94-9027 for the treatment of adults and adolescents (≥12 years) with previously treated hemophilia A. The...

Compared with observation, treatment with intravenous immunoglobulin (IVIg) did not prevent the risk of developing chronic immune thrombocytopenia purpura (ITP) in children newly diagnosed...

Mehdi Hamadani Named Editor of ASH News Daily 2018  Mehdi Hamadani, MD, has been named the 2018 Editor-in- Chief of ASH News Daily, the official...

For the past half-century, plasma products have been the mainstay for the treatment of patients with hemophilia. In the 1950s, hematologists used large volumes...

After a single infusion of AMT-060 (an adeno-associated virus-5 vector carrying a corrected human factor IX gene), patients with hemophilia B experienced...

Treatment with the hemoglobin S polymerization inhibitor voxelotor led to “a remarkable increase in hemoglobin levels” in young patients with sickle cell disease (SCD),...

Sickle cell disease (SCD) is associated with debilitating acute and chronic pain that can occur without warning, frequently sending people to the emergency department...

In an ongoing phase I/II study of patients with hemophilia A, those who received a single infusion of BMN 270 (an adeno-associated virus serotype...

Administration of antifibrinolytic agents, such as tranexamic acid, reduces patients’ risk of death from trauma-related or postpartum bleeding, but delaying time to treatment for...